Related Experiment Video
Updated: Jun 14, 2025
06:39
Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis
Published on: October 27, 2023
896
Recurrent aphthous stomatitis in a child successfully treated with apremilast
Alvaro March-Rodríguez1, Alejandro Lobato-Berezo1, Ramon M Pujol1
1Department of Dermatology, Hospital del Mar, Barcelona, Spain.
Pediatric Dermatology
|September 5, 2024
Summary
Apremilast effectively treated recurrent aphthous stomatitis in a pediatric patient, reducing outbreaks without adverse effects. This case highlights apremilast as a potential therapy for pediatric recurrent aphthous stomatitis.
Area of Science:
- Dermatology
- Pediatric Medicine
- Pharmacology
Background:
- Recurrent aphthous stomatitis (RAS) is a common oral condition causing significant discomfort.
- Previous treatments for pediatric RAS have shown limited efficacy in some cases.
- Apremilast, a phosphodiesterase 4 inhibitor, is approved for certain inflammatory conditions.
Observation:
- A 13-year-old male with a two-year history of severe, recurrent aphthous stomatitis was treated with apremilast.
- The patient had not responded adequately to prior therapeutic interventions.
- The decision was made to initiate apremilast for management of his condition.
Findings:
- The pediatric patient demonstrated a positive clinical response to apremilast therapy.
- A notable reduction in the frequency and severity of aphthous stomatitis outbreaks was observed.
- No adverse effects were reported during the treatment period.
Implications:
- This case represents the first reported use of apremilast for recurrent aphthous stomatitis in a pediatric patient.
- Apremilast shows promise as a safe and effective treatment option for pediatric RAS.
- Further research is warranted to confirm the efficacy and safety of apremilast in a larger pediatric population with RAS.
Related Concept Videos
01:26Peptic Ulcer Disease IV: Management
78
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
78
01:29Drugs for Treatment of Ulcerative Colitis in IBD
130
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
130
01:19Antiasthma Drugs: Leukotriene Modifiers
253
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
253
01:29Inflammatory Bowel Disease IV: Pharmacological Management
122
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
122
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
415
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
415
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
251
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
251